世界のがんバイオ医薬品市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Cancer Biopharmaceuticals Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5641 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、がんバイオ医薬品の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（生物製剤、バイオシミラー）、用途別市場規模（液状がん、固形がん）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・がんバイオ医薬品の市場動向 ・企業の競争状況、市場シェア ・がんバイオ医薬品の種類別市場規模と予測2016-2027（生物製剤、バイオシミラー） ・がんバイオ医薬品の用途別市場規模と予測2016-2027（液状がん、固形がん） ・がんバイオ医薬品の北米市場規模2016-2027（アメリカ、カナダ） ・がんバイオ医薬品の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・がんバイオ医薬品のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・がんバイオ医薬品の中南米市場規模2016-2027（メキシコ、ブラジル） ・がんバイオ医薬品の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Sanofi、Johnson & Johnson、Pfizer、Novartis、Merck、GlaxoSmithKline、Eli Lilly、Agios Pharmaceuticals、Bristol-Myers Squibb、AstraZeneca、Mylan、LEO Pharma、Boehringer Ingelheim、Alexion Pharmaceuticals、Elusys Therapeutics） ・結論

Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Cancer is a complex invasive genetic disease that causes significant mortality rate worldwide. Cancer drugs are the primary concern in terms of drug development trends.

Market Analysis and Insights: Global Cancer Biopharmaceuticals Market
The global Cancer Biopharmaceuticals market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cancer Biopharmaceuticals market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cancer Biopharmaceuticals market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cancer Biopharmaceuticals market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cancer Biopharmaceuticals market.

Global Cancer Biopharmaceuticals Scope and Market Size
Cancer Biopharmaceuticals market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Biopharmaceuticals market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Biologics
Biosimilars

Segment by Application
Liquid Cancers
Solid Cancers

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Sanofi
Johnson & Johnson
Pfizer
Novartis
Merck
GlaxoSmithKline
Eli Lilly
Agios Pharmaceuticals
Bristol-Myers Squibb
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Biopharmaceuticals Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Biologics
1.2.3 Biosimilars
1.3 Market by Application
1.3.1 Global Cancer Biopharmaceuticals Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Liquid Cancers
1.3.3 Solid Cancers
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Cancer Biopharmaceuticals Market Perspective (2016-2027)
2.2 Cancer Biopharmaceuticals Growth Trends by Regions
2.2.1 Cancer Biopharmaceuticals Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Cancer Biopharmaceuticals Historic Market Share by Regions (2016-2021)
2.2.3 Cancer Biopharmaceuticals Forecasted Market Size by Regions (2022-2027)
2.3 Cancer Biopharmaceuticals Industry Dynamic
2.3.1 Cancer Biopharmaceuticals Market Trends
2.3.2 Cancer Biopharmaceuticals Market Drivers
2.3.3 Cancer Biopharmaceuticals Market Challenges
2.3.4 Cancer Biopharmaceuticals Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Cancer Biopharmaceuticals Players by Revenue
3.1.1 Global Top Cancer Biopharmaceuticals Players by Revenue (2016-2021)
3.1.2 Global Cancer Biopharmaceuticals Revenue Market Share by Players (2016-2021)
3.2 Global Cancer Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Cancer Biopharmaceuticals Revenue
3.4 Global Cancer Biopharmaceuticals Market Concentration Ratio
3.4.1 Global Cancer Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Biopharmaceuticals Revenue in 2020
3.5 Cancer Biopharmaceuticals Key Players Head office and Area Served
3.6 Key Players Cancer Biopharmaceuticals Product Solution and Service
3.7 Date of Enter into Cancer Biopharmaceuticals Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Cancer Biopharmaceuticals Breakdown Data by Type
4.1 Global Cancer Biopharmaceuticals Historic Market Size by Type (2016-2021)
4.2 Global Cancer Biopharmaceuticals Forecasted Market Size by Type (2022-2027)

5 Cancer Biopharmaceuticals Breakdown Data by Application
5.1 Global Cancer Biopharmaceuticals Historic Market Size by Application (2016-2021)
5.2 Global Cancer Biopharmaceuticals Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Cancer Biopharmaceuticals Market Size (2016-2027)
6.2 North America Cancer Biopharmaceuticals Market Size by Type
6.2.1 North America Cancer Biopharmaceuticals Market Size by Type (2016-2021)
6.2.2 North America Cancer Biopharmaceuticals Market Size by Type (2022-2027)
6.2.3 North America Cancer Biopharmaceuticals Market Size by Type (2016-2027)
6.3 North America Cancer Biopharmaceuticals Market Size by Application
6.3.1 North America Cancer Biopharmaceuticals Market Size by Application (2016-2021)
6.3.2 North America Cancer Biopharmaceuticals Market Size by Application (2022-2027)
6.3.3 North America Cancer Biopharmaceuticals Market Size by Application (2016-2027)
6.4 North America Cancer Biopharmaceuticals Market Size by Country
6.4.1 North America Cancer Biopharmaceuticals Market Size by Country (2016-2021)
6.4.2 North America Cancer Biopharmaceuticals Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Cancer Biopharmaceuticals Market Size (2016-2027)
7.2 Europe Cancer Biopharmaceuticals Market Size by Type
7.2.1 Europe Cancer Biopharmaceuticals Market Size by Type (2016-2021)
7.2.2 Europe Cancer Biopharmaceuticals Market Size by Type (2022-2027)
7.2.3 Europe Cancer Biopharmaceuticals Market Size by Type (2016-2027)
7.3 Europe Cancer Biopharmaceuticals Market Size by Application
7.3.1 Europe Cancer Biopharmaceuticals Market Size by Application (2016-2021)
7.3.2 Europe Cancer Biopharmaceuticals Market Size by Application (2022-2027)
7.3.3 Europe Cancer Biopharmaceuticals Market Size by Application (2016-2027)
7.4 Europe Cancer Biopharmaceuticals Market Size by Country
7.4.1 Europe Cancer Biopharmaceuticals Market Size by Country (2016-2021)
7.4.2 Europe Cancer Biopharmaceuticals Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Cancer Biopharmaceuticals Market Size (2016-2027)
8.2 Asia-Pacific Cancer Biopharmaceuticals Market Size by Type
8.2.1 Asia-Pacific Cancer Biopharmaceuticals Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Cancer Biopharmaceuticals Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Cancer Biopharmaceuticals Market Size by Type (2016-2027)
8.3 Asia-Pacific Cancer Biopharmaceuticals Market Size by Application
8.3.1 Asia-Pacific Cancer Biopharmaceuticals Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Cancer Biopharmaceuticals Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Cancer Biopharmaceuticals Market Size by Application (2016-2027)
8.4 Asia-Pacific Cancer Biopharmaceuticals Market Size by Region
8.4.1 Asia-Pacific Cancer Biopharmaceuticals Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Cancer Biopharmaceuticals Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Cancer Biopharmaceuticals Market Size (2016-2027)
9.2 Latin America Cancer Biopharmaceuticals Market Size by Type
9.2.1 Latin America Cancer Biopharmaceuticals Market Size by Type (2016-2021)
9.2.2 Latin America Cancer Biopharmaceuticals Market Size by Type (2022-2027)
9.2.3 Latin America Cancer Biopharmaceuticals Market Size by Type (2016-2027)
9.3 Latin America Cancer Biopharmaceuticals Market Size by Application
9.3.1 Latin America Cancer Biopharmaceuticals Market Size by Application (2016-2021)
9.3.2 Latin America Cancer Biopharmaceuticals Market Size by Application (2022-2027)
9.3.3 Latin America Cancer Biopharmaceuticals Market Size by Application (2016-2027)
9.4 Latin America Cancer Biopharmaceuticals Market Size by Country
9.4.1 Latin America Cancer Biopharmaceuticals Market Size by Country (2016-2021)
9.4.2 Latin America Cancer Biopharmaceuticals Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Cancer Biopharmaceuticals Market Size (2016-2027)
10.2 Middle East & Africa Cancer Biopharmaceuticals Market Size by Type
10.2.1 Middle East & Africa Cancer Biopharmaceuticals Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Cancer Biopharmaceuticals Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Cancer Biopharmaceuticals Market Size by Type (2016-2027)
10.3 Middle East & Africa Cancer Biopharmaceuticals Market Size by Application
10.3.1 Middle East & Africa Cancer Biopharmaceuticals Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Cancer Biopharmaceuticals Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Cancer Biopharmaceuticals Market Size by Application (2016-2027)
10.4 Middle East & Africa Cancer Biopharmaceuticals Market Size by Country
10.4.1 Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Cancer Biopharmaceuticals Introduction
11.1.4 Sanofi Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.1.5 Sanofi Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Cancer Biopharmaceuticals Introduction
11.2.4 Johnson & Johnson Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.2.5 Johnson & Johnson Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Cancer Biopharmaceuticals Introduction
11.3.4 Pfizer Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Cancer Biopharmaceuticals Introduction
11.4.4 Novartis Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Cancer Biopharmaceuticals Introduction
11.5.4 Merck Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.5.5 Merck Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Cancer Biopharmaceuticals Introduction
11.6.4 GlaxoSmithKline Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.6.5 GlaxoSmithKline Recent Development
11.7 Eli Lilly
11.7.1 Eli Lilly Company Details
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Cancer Biopharmaceuticals Introduction
11.7.4 Eli Lilly Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.7.5 Eli Lilly Recent Development
11.8 Agios Pharmaceuticals
11.8.1 Agios Pharmaceuticals Company Details
11.8.2 Agios Pharmaceuticals Business Overview
11.8.3 Agios Pharmaceuticals Cancer Biopharmaceuticals Introduction
11.8.4 Agios Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.8.5 Agios Pharmaceuticals Recent Development
11.9 Bristol-Myers Squibb
11.9.1 Bristol-Myers Squibb Company Details
11.9.2 Bristol-Myers Squibb Business Overview
11.9.3 Bristol-Myers Squibb Cancer Biopharmaceuticals Introduction
11.9.4 Bristol-Myers Squibb Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.9.5 Bristol-Myers Squibb Recent Development
11.10 AstraZeneca
11.10.1 AstraZeneca Company Details
11.10.2 AstraZeneca Business Overview
11.10.3 AstraZeneca Cancer Biopharmaceuticals Introduction
11.10.4 AstraZeneca Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.10.5 AstraZeneca Recent Development
11.11 Mylan
11.11.1 Mylan Company Details
11.11.2 Mylan Business Overview
11.11.3 Mylan Cancer Biopharmaceuticals Introduction
11.11.4 Mylan Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.11.5 Mylan Recent Development
11.12 LEO Pharma
11.12.1 LEO Pharma Company Details
11.12.2 LEO Pharma Business Overview
11.12.3 LEO Pharma Cancer Biopharmaceuticals Introduction
11.12.4 LEO Pharma Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.12.5 LEO Pharma Recent Development
11.13 Boehringer Ingelheim
11.13.1 Boehringer Ingelheim Company Details
11.13.2 Boehringer Ingelheim Business Overview
11.13.3 Boehringer Ingelheim Cancer Biopharmaceuticals Introduction
11.13.4 Boehringer Ingelheim Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.13.5 Boehringer Ingelheim Recent Development
11.14 Alexion Pharmaceuticals
11.14.1 Alexion Pharmaceuticals Company Details
11.14.2 Alexion Pharmaceuticals Business Overview
11.14.3 Alexion Pharmaceuticals Cancer Biopharmaceuticals Introduction
11.14.4 Alexion Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.14.5 Alexion Pharmaceuticals Recent Development
11.15 Elusys Therapeutics
11.15.1 Elusys Therapeutics Company Details
11.15.2 Elusys Therapeutics Business Overview
11.15.3 Elusys Therapeutics Cancer Biopharmaceuticals Introduction
11.15.4 Elusys Therapeutics Revenue in Cancer Biopharmaceuticals Business (2016-2021)
11.15.5 Elusys Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Cancer Biopharmaceuticals Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Biologics
Table 3. Key Players of Biosimilars
Table 4. Global Cancer Biopharmaceuticals Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Cancer Biopharmaceuticals Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Cancer Biopharmaceuticals Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Cancer Biopharmaceuticals Market Share by Regions (2016-2021)
Table 8. Global Cancer Biopharmaceuticals Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Cancer Biopharmaceuticals Market Share by Regions (2022-2027)
Table 10. Cancer Biopharmaceuticals Market Trends
Table 11. Cancer Biopharmaceuticals Market Drivers
Table 12. Cancer Biopharmaceuticals Market Challenges
Table 13. Cancer Biopharmaceuticals Market Restraints
Table 14. Global Cancer Biopharmaceuticals Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Cancer Biopharmaceuticals Market Share by Players (2016-2021)
Table 16. Global Top Cancer Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Biopharmaceuticals as of 2020)
Table 17. Ranking of Global Top Cancer Biopharmaceuticals Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Cancer Biopharmaceuticals Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Cancer Biopharmaceuticals Product Solution and Service
Table 21. Date of Enter into Cancer Biopharmaceuticals Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Cancer Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Cancer Biopharmaceuticals Revenue Market Share by Type (2016-2021)
Table 25. Global Cancer Biopharmaceuticals Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Cancer Biopharmaceuticals Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Cancer Biopharmaceuticals Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Cancer Biopharmaceuticals Revenue Market Share by Application (2016-2021)
Table 29. Global Cancer Biopharmaceuticals Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Cancer Biopharmaceuticals Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Cancer Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Cancer Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Cancer Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Cancer Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Cancer Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Cancer Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Cancer Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Cancer Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Cancer Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Cancer Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Cancer Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Cancer Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Cancer Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Cancer Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Cancer Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Cancer Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Cancer Biopharmaceuticals Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Cancer Biopharmaceuticals Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Cancer Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Cancer Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Cancer Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Cancer Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Cancer Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Cancer Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Cancer Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Cancer Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Cancer Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Cancer Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million)
Table 61. Sanofi Company Details
Table 62. Sanofi Business Overview
Table 63. Sanofi Cancer Biopharmaceuticals Product
Table 64. Sanofi Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 65. Sanofi Recent Development
Table 66. Johnson & Johnson Company Details
Table 67. Johnson & Johnson Business Overview
Table 68. Johnson & Johnson Cancer Biopharmaceuticals Product
Table 69. Johnson & Johnson Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 70. Johnson & Johnson Recent Development
Table 71. Pfizer Company Details
Table 72. Pfizer Business Overview
Table 73. Pfizer Cancer Biopharmaceuticals Product
Table 74. Pfizer Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 75. Pfizer Recent Development
Table 76. Novartis Company Details
Table 77. Novartis Business Overview
Table 78. Novartis Cancer Biopharmaceuticals Product
Table 79. Novartis Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 80. Novartis Recent Development
Table 81. Merck Company Details
Table 82. Merck Business Overview
Table 83. Merck Cancer Biopharmaceuticals Product
Table 84. Merck Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 85. Merck Recent Development
Table 86. GlaxoSmithKline Company Details
Table 87. GlaxoSmithKline Business Overview
Table 88. GlaxoSmithKline Cancer Biopharmaceuticals Product
Table 89. GlaxoSmithKline Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 90. GlaxoSmithKline Recent Development
Table 91. Eli Lilly Company Details
Table 92. Eli Lilly Business Overview
Table 93. Eli Lilly Cancer Biopharmaceuticals Product
Table 94. Eli Lilly Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 95. Eli Lilly Recent Development
Table 96. Agios Pharmaceuticals Company Details
Table 97. Agios Pharmaceuticals Business Overview
Table 98. Agios Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 99. Agios Pharmaceuticals Recent Development
Table 100. Bristol-Myers Squibb Company Details
Table 101. Bristol-Myers Squibb Business Overview
Table 102. Bristol-Myers Squibb Cancer Biopharmaceuticals Product
Table 103. Bristol-Myers Squibb Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 104. Bristol-Myers Squibb Recent Development
Table 105. AstraZeneca Company Details
Table 106. AstraZeneca Business Overview
Table 107. AstraZeneca Cancer Biopharmaceuticals Product
Table 108. AstraZeneca Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 109. AstraZeneca Recent Development
Table 110. Mylan Company Details
Table 111. Mylan Business Overview
Table 112. Mylan Cancer Biopharmaceuticals Product
Table 113. Mylan Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 114. Mylan Recent Development
Table 115. LEO Pharma Company Details
Table 116. LEO Pharma Business Overview
Table 117. LEO Pharma Cancer Biopharmaceuticals Product
Table 118. LEO Pharma Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 119. LEO Pharma Recent Development
Table 120. Boehringer Ingelheim Company Details
Table 121. Boehringer Ingelheim Business Overview
Table 122. Boehringer Ingelheim Cancer Biopharmaceuticals Product
Table 123. Boehringer Ingelheim Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 124. Boehringer Ingelheim Recent Development
Table 125. Alexion Pharmaceuticals Company Details
Table 126. Alexion Pharmaceuticals Business Overview
Table 127. Alexion Pharmaceuticals Cancer Biopharmaceuticals Product
Table 128. Alexion Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 129. Alexion Pharmaceuticals Recent Development
Table 130. Elusys Therapeutics Company Details
Table 131. Elusys Therapeutics Business Overview
Table 132. Elusys Therapeutics Cancer Biopharmaceuticals Product
Table 133. Elusys Therapeutics Revenue in Cancer Biopharmaceuticals Business (2016-2021) & (US$ Million)
Table 134. Elusys Therapeutics Recent Development
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer Biopharmaceuticals Market Share by Type: 2020 VS 2027
Figure 2. Biologics Features
Figure 3. Biosimilars Features
Figure 4. Global Cancer Biopharmaceuticals Market Share by Application: 2020 VS 2027
Figure 5. Liquid Cancers Case Studies
Figure 6. Solid Cancers Case Studies
Figure 7. Cancer Biopharmaceuticals Report Years Considered
Figure 8. Global Cancer Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global Cancer Biopharmaceuticals Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Cancer Biopharmaceuticals Market Share by Regions: 2020 VS 2027
Figure 11. Global Cancer Biopharmaceuticals Market Share by Regions (2022-2027)
Figure 12. Global Cancer Biopharmaceuticals Market Share by Players in 2020
Figure 13. Global Top Cancer Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Biopharmaceuticals as of 2020
Figure 14. The Top 10 and 5 Players Market Share by Cancer Biopharmaceuticals Revenue in 2020
Figure 15. Global Cancer Biopharmaceuticals Revenue Market Share by Type (2016-2021)
Figure 16. Global Cancer Biopharmaceuticals Revenue Market Share by Type (2022-2027)
Figure 17. North America Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America Cancer Biopharmaceuticals Market Share by Type (2016-2027)
Figure 19. North America Cancer Biopharmaceuticals Market Share by Application (2016-2027)
Figure 20. North America Cancer Biopharmaceuticals Market Share by Country (2016-2027)
Figure 21. United States Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Cancer Biopharmaceuticals Market Share by Type (2016-2027)
Figure 25. Europe Cancer Biopharmaceuticals Market Share by Application (2016-2027)
Figure 26. Europe Cancer Biopharmaceuticals Market Share by Country (2016-2027)
Figure 27. Germany Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Cancer Biopharmaceuticals Market Share by Type (2016-2027)
Figure 35. Asia-Pacific Cancer Biopharmaceuticals Market Share by Application (2016-2027)
Figure 36. Asia-Pacific Cancer Biopharmaceuticals Market Share by Region (2016-2027)
Figure 37. China Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Cancer Biopharmaceuticals Market Share by Type (2016-2027)
Figure 45. Latin America Cancer Biopharmaceuticals Market Share by Application (2016-2027)
Figure 46. Latin America Cancer Biopharmaceuticals Market Share by Country (2016-2027)
Figure 47. Mexico Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Cancer Biopharmaceuticals Market Share by Type (2016-2027)
Figure 51. Middle East & Africa Cancer Biopharmaceuticals Market Share by Application (2016-2027)
Figure 52. Middle East & Africa Cancer Biopharmaceuticals Market Share by Country (2016-2027)
Figure 53. Turkey Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE Cancer Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Sanofi Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 57. Johnson & Johnson Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 58. Pfizer Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 59. Novartis Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 60. Merck Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 61. GlaxoSmithKline Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 62. Eli Lilly Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 63. Agios Pharmaceuticals Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 64. Bristol-Myers Squibb Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 65. AstraZeneca Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 66. Mylan Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 67. LEO Pharma Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 68. Boehringer Ingelheim Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 69. Alexion Pharmaceuticals Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 70. Elusys Therapeutics Revenue Growth Rate in Cancer Biopharmaceuticals Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

---